Since the turn of the century, attempts have been made to modify the patient's host defense mechanisms to his tumour. Despite occasional anecdotal reports of antitumour activity of such an approach, larger studies have failed to demonstrate convincing efficacy for these non-specific immunostimulants. During the last 5 years, tremendous advances have been made in molecular biology which, for the first time, has allowed the production of biological molecules in very pure form. For the first time, research both in the laboratory and the clinic using these reagents is beginning to unravel the relationship between the immune system and the tumour. In this article we will review the current status of laboratory and clinical research with biological response modifiers and attempt to suggest ways in which new, novel and hopefully more effective therapies for cancer may be developed. Neth J Med 1988,33:41-47.
|Original language||English (US)|
|Number of pages||7|
|Journal||Netherlands Journal of Medicine|
|State||Published - Jul 1988|
- Biological response modifier
ASJC Scopus subject areas